Are we there yet? Advanced technologies for young children with type 1 diabetes: comment in response to "Type 1 diabetes mellitus management in young children: implementation of current technologies".
Are we there yet? Advanced technologies for young children with type 1 diabetes: comment in response to "Type 1 diabetes mellitus management in young children: implementation of current technologies".
复制标题
我们到了吗?
DOI:
10.1038/s41390-020-0787-8
复制
发表时间:
2020
影响因子:
3.6
通讯作者:
Artman,Michael
中科院分区:
文献类型:
--
作者:
Clements,MarkA;Patton,SusanaR;McDonough,RyanJ;Artman,Michael
The paper by Nevo-Shenker et al. 1 presents the evidence available to support use of recently developed diabetes self-management technologies in very young children (< age 6-years-old) with type 1 diabetes (T1D). The specific technologies the authors write about include continuous glucose monitors (CGMs), continuous subcutaneous insulin infusion (CSII; aka insulin pump) therapy, sensoraugmented pump (SAP) therapy, predictive low-glucose suspend (PLGS) technology, and hybrid closed loop (HCL) insulin delivery. While the authors present promising early evidence for each technology, the limited number of studies, the small samples of young children in those studies, the limited cognitive and behavioral phenotyping of the children and caregivers in the studies, the lack of technologies designed specifically for young children, and the continued lack of well-designed longitudinal randomized clinical trials specifically addressing safety and efficacy in young children remain problematic. Collectively, these limitations constitute critical gaps in our approaches to optimizing care for young children with T1D and evoke multiple research questions that must be explored.